As we move deeper into 2025, biosimilars are gaining unprecedented traction.Read More
Biosimilars are near-identical versions of approved biologics, offering similar safety, efficacy, and quality—but at a lower cost. Unlike generics, biosimilars are made from living cells and require complex development and regulatory approval.Read More